CClinicalTrials.gg
CompletedNCT05570578Updated May 4, 2026

Effects of Transcranial Direct Current Stimulation (tDCS) on Brain Organization and Naming in Aphasic Patients.

An interventional study of HD-tDCS in Stroke and Aphasia, sponsored by Adrian Guggisberg. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Adrian Guggisberg · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

High-Definition Transcranial Direct Current Stimulation (HD-tDCS) allows to induce, in a non-invasive way, a transient inhibitory or excitatory neuromodulation of a given cerebral region and to obtain a very focused cortical effect. Previous studies using HD-tDCS have shown the effectiveness of this stimulation technique for enhancing language recovery in patients with aphasia.

However, language processes are not determined solely by local neural activity at a single site, but rather by the interaction between neural networks. This is because a large cortical network is involved in language processes and, therefore, the same language disorder may result from lesions at different locations in this network.

The investigators hypothesize that anodal HD-tDCS will enhance neural interactions between language areas and, thereby, improve language processing and word learning.

The investigators propose to carry out a study on chronic aphasic patients involving HD-tDCS of the Broca region (left inferior frontal gyrus) combined with a verb learning task.

Read the detailed description

Functional connectivity (FC) represents a means of analyzing functional interactions in the brain network by assessing the statistical dependence of neural activity between brain areas. The brain maintains a high level of interactions between brain areas even in the resting state, when it is not explicitly involved in a specific task. Resting-state interactions occur mainly in the so-called alpha frequency band (8-13 Hz) . Moreover, these resting-state interactions are crucial for correct task performance and learning. Indeed, healthy subjects with high resting-state alpha-band FC levels are better able to perform tasks and learn. For example, subjects with high levels of FC between Broca's area and the rest of the brain perform better on language production tasks and show greater training gains when learning new words. In addition, patients with brain damage due to stroke show a reduction in resting-state alpha-band FC, which correlates with the severity of neurological deficits. In particular, a loss of FC of structurally preserved inferior frontal areas was associated with more severe aphasia. Conversely, high-levels of FC between the inferior frontal brain areas and the rest of the brain during the first weeks after stroke was associated with better recovery from aphasia, probably reflecting a reorganization of neural connections as a neural mechanism involved in plasticity. Resting-state FC is therefore an interesting neural target for therapy, which could help improve recovery from aphasia.

In a previous study on healthy subjects, the investigators have indeed observed that HD-tDCS applied to Broca's area improves the ability for new-verb learning, i.e., the correct naming of action pictures. This improvement in learning correlated with greater increase in FC between Broca's and Wernicke's area.

The investigators now carry out a study on chronic aphasic patients involving HD-tDCS of the Broca region (left inferior frontal gyrus) combined with a verb learning task.

02

Conditions studied

  • Stroke
  • Aphasia

Browse trials for

Keywords

  • tDCS
  • Functional connectivity
  • EEG
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's enrollment of 14 is below the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Adrian Guggisberg is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Ischemic or hemorrhagic stroke
  • Presence of aphasia with difficulty finding words and/or naming objects/pictures
  • ≥12 months post-stroke
  • ≥ 18 years of age
  • French-speaking
  • Able to participate in 30-60 min therapeutic sessions (good concentration and understanding of the task and ability to follow instructions

Exclusion criteria

Exclusion Criteria:

  • Patients unable to understand the given information on the study and its objectives, or instructions for tasks performed.
  • Impaired alertness or delirium
  • Severe co-morbidity affecting speech
  • Contraindication to tDCS: pregnant women, patients with active implants such as pacemakers or cochlear implants, patients with one or more seizures, metal objects in the brain
  • Occurrence of a new stroke during the study protocol.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Active comparator
    HD-tDCS

    high-density transcranial direct current stimulation (HD-tDCS) over Broca's area

    Device: HD-tDCS

  • Sham comparator
    sham-tDCS

    sham transcranial direct current stimulation. The same setup will be used as in the HD-tDCS arm, except that the current will be ramped up for 30 seconds and then switched off. This does not lead to neural effects, but the patients have a similar sensation.

    Device: HD-tDCS

Interventions

  • DeviceHD-tDCS

    The anode electrode will be placed over Broca's area, 4 cathode electrodes will be placed at about 2 cm distance each from the anode in 4 directions.

    Also known as: high-density transcranial direct current stimulation, DC-stimulator

06

What researchers measure

Primary outcomes

  1. Action picture naming, short-term improvement

    Change in number of correctly named action pictures

    Time frame: Change from day 1 (baseline) to day 5 (posttest)

Secondary outcomes

  1. Functional connectivity between Broca's and Wernicke's area

    Change in the normalized imaginary component of coherence between Broca and Wernicke

    Time frame: Change from day 1 (baseline) to day 5 (posttest)

Other outcomes

  1. Action picture naming, long-term improvement

    Change in number of correctly named action pictures

    Time frame: Change from day 1 (baseline) to week 4 (follow-up)

  2. Narrative speech, short-term improvement

    Patient describes cookie-theft picture and action-picture, change in score

    Time frame: Change from day 1 (baseline) to day 5 (posttest)

  3. Narrative speech, long-term improvement

    Patient describes cookie-theft picture and action-picture, change in score

    Time frame: Change from day 1 (baseline) to week 4 (follow-up)

07

Study locations

1 site
  • Division of Neurorehabilitation, University Hospital of Geneva
    Geneva, Canton of Geneva 1211, Switzerland
08

References and documents

Individual participant data

Plan to share: Yes — Published and analyzed data will be archived in a secure location on a data sharing server that meets the FAIR (Findability, Accessibility, Interoperability, and Reuse) principles for a minimum of 10 years.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05570578
Lead sponsor
Adrian Guggisberg
Responsible party
Adrian Guggisberg (Médecin conseil, University Hospital, Geneva) — Sponsor-investigator
First posted
Oct 6, 2022
Start date
Oct 24, 2022
Primary completion
Feb 1, 2026
Completion
Apr 1, 2026
Last update
May 4, 2026

Study contacts

Adrian G Guggisberg, MD
principal investigator · University of Geneva, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion